Skip to content

Dihydrocodeine

Published: July 26, 2026Updated: August 24, 2026

Dihydrocodeine is a semi-synthetic opioid analgesic used to treat moderate to severe pain. It works by binding to opioid receptors in the brain and nervous system to reduce the perception of pain. This medication is typically prescribed when non-opioid pain relievers are insufficient.

Quick summary

Dihydrocodeine is an opioid pain medication for moderate to severe pain.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 24, 2026Editorial policy
BOXED WARNING

This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.

Key facts at a glance

ATC
N02AA08
RxNorm
23088
Generic
Dihydrocodeine
Class
atc-n02
Brands
Trezix
Availability
rx
Pregnancy
C
Lactation
caution
Routes
oral
Forms
capsule, tablet, solution
Regions
US, EU, CN, JP
Monitoring
—

This page is for informational purposes only.

Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.

Dosage and administration

adult (standard)tablet
Usual dose
30mg every 4-6 hours as needed
Maximum
consult physician
Frequency
every 4-6 hours
Instructions
Follow physician instructions
Duration limits
as prescribed
Monitoring
standard
pediatric (standard)tablet
Usual dose
Not recommended under 12 years
Maximum
consult physician
Frequency
N/A
Instructions
Follow physician instructions
Duration limits
as prescribed
Monitoring
standard
geriatric (standard)tablet
Usual dose
30mg every 6-8 hours
Maximum
consult physician
Frequency
every 6-8 hours
Instructions
Follow physician instructions
Duration limits
as prescribed
Monitoring
standard

Overdose information

Important overdose information
Toxic dose: Single dose that may cause serious toxicity in adults
Chronic overdose: Prolonged use leading to tolerance and accumulation
Immediate actions
Secure airway, administer naloxone, gastric decontamination if within 1-2 hours, supportive care including ventilation
Antidote
Naloxone(Reverses respiratory depression within 1-5 minutes of administration)
Poison Control: 1-800-222-1222

Special Populations

10 groups
✗

pregnancy

first trimester
unsafe
FDA Category
C
Dose Adjustment

avoid if possible

Key Recommendations

avoid use during pregnancy unless benefits outweigh risks, use lowest effective dose for shortest duration

Monitor

regular fetal monitoring

Use of this medication in this population requires careful consideration of risks and benefits.

✗

pregnancy

third trimester
unsafe
FDA Category
C
Dose Adjustment

avoid if possible

Key Recommendations

avoid use near delivery due to risk of neonatal respiratory depression and withdrawal

Monitor

close fetal monitoring, assess for neonatal abstinence syndrome

Use of this medication in this population requires careful consideration of risks and benefits.

✗

lactation

breastfeeding
unsafe
FDA Category
C
Dose Adjustment

avoid

Key Recommendations

dihydrocodeine is excreted in breast milk, avoid breastfeeding during treatment

Monitor

monitor infant for excessive sleepiness, breathing difficulties, or feeding problems

Use of this medication in this population requires careful consideration of risks and benefits.

⚠

geriatric

elderly
caution
FDA Category
N
Dose Adjustment

reduce initial dose by 25-50%, increase slowly

Key Recommendations

use with caution due to increased sensitivity, start with low doses, monitor for adverse effects

Monitor

regular assessment of pain control, respiratory status, and cognitive function

Use with caution and monitor for adverse effects.

✗

pediatric_age

under 12 years
contraindicated
FDA Category
N
Dose Adjustment

not recommended

Key Recommendations

do not use in children under 12 years due to risk of severe respiratory depression

Monitor

not applicable

Use of this medication in this population requires careful consideration of risks and benefits.

⚠

pediatric_age

adolescents 12 to 18
caution
FDA Category
N
Dose Adjustment

use with caution, consider weight-based dosing

Key Recommendations

use only if benefits outweigh risks, monitor closely for respiratory depression

Monitor

close monitoring for signs of respiratory depression and sedation

Use with caution and monitor for adverse effects.

⚠

renal_impairment

mild to moderate
caution
FDA Category
N
Dose Adjustment

reduce dose by 25-50%

Key Recommendations

use with caution, adjust dosing interval, monitor for accumulation

Monitor

monitor renal function, assess for opioid toxicity

Use with caution and monitor for adverse effects.

✗

renal_impairment

severe
unsafe
FDA Category
N
Dose Adjustment

avoid or use with significant dose reduction

Key Recommendations

use only if benefits clearly outweigh risks, consider alternative analgesics

Monitor

frequent monitoring of drug levels and renal function

Use of this medication in this population requires careful consideration of risks and benefits.

⚠

hepatic_impairment

mild to moderate
caution
FDA Category
N
Dose Adjustment

reduce dose by 25-50%

Key Recommendations

use with caution, impaired hepatic metabolism may alter drug effects

Monitor

monitor liver function and opioid response

Use with caution and monitor for adverse effects.

✗

hepatic_impairment

severe
unsafe
FDA Category
N
Dose Adjustment

avoid

Key Recommendations

avoid use in severe hepatic impairment due to unpredictable metabolism

Monitor

not applicable

Use of this medication in this population requires careful consideration of risks and benefits.

Statistics and clinical data

prescribingFDA
2023

Commonly prescribed since

Value:1950s

General prescribing information for dihydrocodeine products

drug_classWHO
2023

Drug class

Value:Opioid analgesic

WHO ATC Classification System - Opioid analgesics

usageMedical guidelines
2023

Common uses

Value:Moderate to severe pain relief, cough suppression

Common therapeutic uses for dihydrocodeine

pharmacologyFDA
2023

Potency relative to codeine

Value:1.5 times more potent

Pharmacological potency comparison

Treatment of moderate to severe pain, including postoperative pain, trauma pain, and pain from conditions such as cancer or musculoskeletal disorders. May also be used as a cough suppressant at lower doses.

Acts on mu-opioid receptors in the central nervous system to alter pain perception and emotional response to pain. Produces analgesia, sedation, and respiratory depression similar to other opioid medications.

Carries risk of dependence, tolerance, and addiction with prolonged use. Common side effects include drowsiness, constipation, nausea, and respiratory depression. Should be used with caution in patients with respiratory conditions, liver or kidney impairment, and should not be combined with alcohol or other CNS depressants.

Contraindications

Conditions and patient states where this medication should be avoided or used with caution.

Do not use (1)

ABSOLUTEhypersensitivity

Known allergy to this medication or its components

Use caution (1)

RELATIVEpregnancy

Consult healthcare provider for benefits vs risks assessment

Official drug label

WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 24, 2026. · Read our editorial policy